Table 2

Rates of symptoms and Global Distress assessed by FPS-R at baseline and after treatment
Symptoms Baseline At the end of treatment
α-galactosidase Placebo p-value α-galactosidase Placebo p-value
(N = 27) (N = 25) (N = 27) (N = 25)
Flatulence*: n, (%) 16 (59%) 12 (48%) p = 0.42 5 (19%) 12 (48%) p = 0.02^
Abdominal distension**: n, (%) 12 (44%) 14 (56%) p = 0.41 8 (30%) 11 (44%) p = 0.36
Abdominal spasm***: n, (%) 14 (52%) 14 (56%) p = 0.76 4 (15%) 4 (16%) p = 0.91
FPS-R, mean ± SD 2.8 ± 1.8 2.3 ± 0.9 p = 0.22 2.0 ± 1.7 2.1 ± 1.1 p = 0.73
Difference between FPS-R at baseline and after treatment −0.8 ± 1.1 −0.2 ± 0.8 p = 0.02^
Number of days with severe bloating during treatment (mean ± SD) 3.4 ± 3.6 5.4 ± 3.4 p = 0.03^

*patients with significant episodes (score of > 2) of flatulence ≥ 3 days/week.

**patients with visible abnormal distension ≥ 3 days/week.

***patients with abdominal spasm ≥ 3 days/week.

mean of 21 measurements for each patient.

^p value < 0.05 was considered statistically significant.

Di Nardo et al.

Di Nardo et al. BMC Gastroenterology 2013 13:142   doi:10.1186/1471-230X-13-142

Open Data